EINDHOVEN, Netherlands,
Sept. 13, 2021 /PRNewswire/ --
STENTiT, a medical device company bringing a novel class of
regenerative endovascular implants for treatment of cardiovascular
diseases, today announced the appointment of its Medical
Advisory Board, chaired by Prof. Patrick
Serruys and complemented by Prof. Marc van Sambeek and Prof. Yoshinobu Onuma.
Bart Sanders, CEO of STENTiT,
said: "We are excited to receive the support of these
highly esteemed professionals in the current stage of our company
development."
"What is fascinating about STENTiT's technology, is the
presence of endoluminal elastin in early preclinical work.
Restoring this protective layer in patients would be a unique
approach to prevent late-stage neo-atherosclerosis,":
says Prof. Serruys, Chairman of the Board, Global Key Opinion
Leader and established professor of interventional medicine and
innovation from the CORRIB Core Lab of the National University of Ireland Galway.
"Providing a new regenerative inner surface of the vessel,
may be key to improve patency outcomes in peripheral interventions,
where so far current alternatives are
suboptimal," adds Prof. van Sambeek, vascular
surgeon at the Catherina Hospital in Eindhoven, the Netherlands, and part-time professor of
Application of Engineering in Vascular Surgery and Endovascular
Therapy from the department of Biomedical Engineering at the
Eindhoven University of Technology.
"STENTiT will be one of the unique technologies to overcome
the limitations of first generation resorbable devices,"
states Prof. Onuma, Professor of interventional cardiology and
medical director of Coronary Imaging and Atherosclerosis Research
of the CORRIB Core Lab from the National
University of Ireland Galway.
Bart Sanders further
concludes: "In the ongoing quest to improve sustained
vascular patency, regenerative stents provide a unique approach in
combining regenerative medicine with bioresorbable stent
technology. By providing temporary scaffolding while simultaneously
restoring the artery from the inside-out, we could significantly
improve durable clinical outcomes."
About the members of the Medical Advisory Board:
Prof. Serruys (Left) is a world-renowned expert in
interventional cardiology and imaging with more than four decades
of experience in clinical trials and innovation in medicine. He
pioneered several interventional procedures and devices such as
BMS, DES, BRS and TAVI as well as imaging techniques including
quantitative coronary angiography, quantitative IVUS, OCT, and near
spectroscopy combined with IVUS. Furthermore, Prof. Serruys
conducted over 90 clinical trials including over 191,000 patients,
is the co-author of more than 4000 peer-reviewed publications and
additionally is the author, co-author and editor of more than 42
books including the textbook of the European Society of Cardiology.
Earlier in his carrier, for 20 years Prof. Serruys was the chief of
department of interventional cardiology at the Thoraxcenter
Rotterdam and been awarded several gold medals including the ESC
and ACC career achievements awards.
Prof. van Sambeek (Middle) is an expert vascular surgeon
at the Catharina Hospital Eindhoven with a special focus on
minimally invasive vascular surgery and is a part-time professor of
Application of Engineering in Vascular Surgery and Endovascular
Therapy at the Cardiovascular Biomechanics research group of the
department of Biomedical Engineering from the Eindhoven University
of Technology. He is an active scientific researcher who initiated
and participated in many clinical studies. Prof. van Sambeek is
(co-)author of more than 200 publications in peer-reviewed medical
journals and more than 20 chapters in medical textbooks. He is a
member of the editorial board of several international journals,
co-founder of the Endovascular Forum, founding member of the
International Society of Vascular Surgery and was a board member of
the Dutch Association for Vascular Surgery, EuroPCR and European
Association for Percutaneous Cardiovascular Interventions.
Prof. Onuma (Right) is a
leading expert in the field of non-invasive and invasive coronary
imaging and novel coronary devices such as bioresorbable scaffolds.
His expertise includes quantitative coronary angiography
(2-dimensional, 3-dimensional and bifurcation-dedicated), Syntax
Score and multi-slice computed tomography. Prof. Onuma received his
medical degree from Tohoku University School of Medicine in Sendai,
Japan. After his cardiology and
interventional cardiology fellowship, he joined the Erasmus University of Rotterdam and was granted a doctorate in
interventional cardiology. Prof. Onuma published over 500
manuscripts in peer-reviewed journals and is the author and editor
of several books including the textbook of bioresorbable
scaffold.
About STENTiT:
STENTiT is a medical device spin-off company from the Dutch
Eindhoven University of Technology, focusing on the development of
regenerative endovascular implants. These bioresorbable devices
trigger a natural healing response by the circulating blood cells,
in which the implant is being replaced by new vascular tissue to
restore the artery from the inside-out.
Since the establishment of the company in 2017, STENTiT has
received broad international recognition and awards for its
high-potential approach, covering world leading stages. As the
company is currently going through the next translational phases,
STENTiT is on its way to fulfill its ambition to become the new
standard in endovascular treatment, providing a life-lasting
solution for millions of patients around the world.
More information is available at www.stentit.com
For further enquiries, please contact:
STENTiT |
Eindhoven, The
Netherlands
Dr. Bart
Sanders, CEO
T: +31 40 247 2445
E: b.sanders@stentit.com
For media:
LifeSpring Life Sciences Communication |
Amsterdam, The
Netherlands
Léon Melens
T: +31 6 538 16 427
E: lmelens@lifespring.nl
Photo -
https://mma.prnewswire.com/media/1623473/STENTiT_Medical_Advisory_Board.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtech-company-stentit-announces-the-appointment-of-a-medical-advisory-board-chaired-by-prof-patrick-serruys-and-complemented-by-prof-marc-van-sambeek-and-prof-yoshinobu-onuma-301374911.html
SOURCE STENTiT
